跳转至内容
Merck
CN

95102433

BEAS-2B Cell Line human

NOTE: Both the cell line and DNA from the cell line may be available for this product. Please choose -1VL or VIAL for cells, or -DNA-5UG for DNA.

登录 查看组织和合同定价。

选择尺寸


关于此项目

UNSPSC Code:
41106514
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

BEAS-2B Cell Line human, NOTE: Both the cell line and DNA from the cell line may be available for this product. Please choose -1VL or VIAL for cells, or -DNA-5UG for DNA.

biological source

human lung

description

Human bronchial epithelium, normal

form

liquid

packaging

tube of 5 μg 95102433-DNA-5UG
pkg of vial of cells 95102433-1VL

growth mode

Adherent

karyotype

Not specified

morphology

Epithelial-like

products

Not specified

receptors

Not specified

technique(s)

cell culture | mammalian: suitable

Quality Level

Application

BEAS-2B Cell line has been used to study differentiation of squamous cells and effect of biological and chemical agents on differentiation.

Biochem/physiol Actions

BEAS-2B cells were derived from normal bronchial epithelium obtained from autopsy of non-cancerous individuals. Cells were infected with a replication-defective SV40/adenovirus 12 hybrid and cloned. Squamous differentiation can be observed in response to serum. This ability can be used for screening chemical and biological agents inducing or affecting differentiation and/or carcinogenesis. The cell line has been applied for studies of pneumococcal infection mechanisms. BEAS-2B was described to express keratins and SV40 T antigen. Subculturing the cells before confluency is necessary as confluent cultures rapidly undergo squamous terminal differentiation.
Human bronchial epithelium, normal
STR-PCR Data: Amelogenin: X,Y
CSF1PO: 9,12
D13S317: 13
D16S539: 12
D5S818: 12,13
D7S820: 10,13
THO1: 7,9.3
TPOX: 6,11
vWA: 17,18

Disclaimer

RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.

Other Notes

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.
Cultures from HPA Culture Collections and supplied by Sigma are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line.
Please view the Terms & Conditions of Supply for more information.

Packaging

NOTE: Both the cell line and DNA from the cell line may be available for this product. Please choose -1VL or VIAL for cells, or -DNA-5UG for DNA.

Preparation Note

BEGM, also known as LHC-9 with modification (available from Clonetics Corporation, CC3171 (BEBM) plus additives CC4175 or BEGM Bullet Kit, CC3170); Note: Additives supplied contain gentamycin which has been omitted for culture at ECACC; media is serum-free.
Passage sub-confluent cultures using 0.25% trypsin or trypsin/EDTA. Incubate at room temperature for 5-10 min until cells detach. Add fresh medium and disperse cells, centrifuge and resuspend pellet in medium. Seed into new flasks at 1500 to 3000 cells per cm2. Flasks have to be precoated with a mixture of 0.01 mg/ml fibronectin, 0.03 mg/ml collagen and 0.001 mg/ml bovine serum albumin dissolved in BEGM. Add mixture at ratio of 0.2 ml per cm2 surface area. Incubate at 5% CO2, 37°C for at least 6 hours at 37oC. Remove excess fluid and allow flasks to dry by incubating at 37oC overnight, leaving the caps loose. Prior to addition of cells wash flask three times with PBS. Note: BEGM medium is almost serum-free, therefore trypsin inhibitor is essential. Add an equal or greater volume of trypsin inhibitor as trypsin used before, centrifuge and reseed cells in collagen coated flasks using culture medium.

存储类别

10 - Combustible liquids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

An antagonist of the platelet-activating factor receptor inhibits adherence of both nontypeable Haemophilus influenzae and Streptococcus pneumoniae to cultured human bronchial epithelial cells exposed to cigarette smoke
Shakti D Shukla
International Journal of Chronic Obstructive Pulmonary Disease, 11 (2016)
Induction of altered mRNA expression profiles caused by fibrous and granular dust
Simone Helmig
Molecular Medicine Reports (2013)
J E Adamou et al.
Infection and immunity, 66(2), 820-822 (1998-02-07)
Pneumococcal adherence to alveolar epithelial cells and nasopharyngeal epithelial cells has been well characterized. However, the interaction of Streptococcus pneumoniae with bronchial epithelial cells has not been studied. We have now shown that pneumococci bind specifically to a human bronchial
Björn Klabunde et al.
Nature communications, 14(1), 5818-5818 (2023-10-03)
Lower respiratory tract infections caused by Streptococcus pneumoniae (Spn) are a leading cause of death globally. Here we investigate the bronchial epithelial cellular response to Spn infection on a transcriptomic, proteomic and metabolic level. We found the NAD+ salvage pathway
Yu-Jung Lin et al.
Heliyon, 9(9), e20011-e20011 (2023-10-09)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused 403 million cases of coronavirus disease (COVID-19) and resulted in more than 5.7 million deaths worldwide. Extensive research has identified several potential drug treatments for COVID-19. However, the development of new

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持